These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36805801)

  • 1. Improving pain control during transarterial chemoembolization for hepatocellular carcinoma performed under local anesthesia with multimodal analgesia.
    Vanderbecq Q; Grégory J; Dana J; Dioguardi Burgio M; Garzelli L; Raynaud L; Frémy S; Paulatto L; Bouattour M; Kavafyan-Lasserre J; Vilgrain V; Ronot M
    Diagn Interv Imaging; 2023 Mar; 104(3):123-132. PubMed ID: 36805801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma.
    Pachev A; Raynaud L; Paulatto L; Dioguardi Burgio M; Roche V; Garcia Alba C; Sibert A; Lagadec M; Kavafyan-Lasserre J; Paugam-Burtz C; Vilgrain V; Ronot M
    Eur Radiol; 2021 May; 31(5):3267-3275. PubMed ID: 33123789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?
    Chen S; Peng Z; Zhang Y; Chen M; Li J; Guo R; Li J; Li B; Mei J; Feng S; Kuang M
    Radiology; 2021 Mar; 298(3):680-692. PubMed ID: 33464183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoembolization for hepatocellular carcinoma: effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization.
    Romano M; Giojelli A; Tamburrini O; Salvatore M
    Radiol Med; 2003 Apr; 105(4):350-5. PubMed ID: 12835628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
    Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
    Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma.
    Simasingha N; Tanasoontrarat W; Claimon T; Sethasine S
    World J Gastroenterol; 2023 Feb; 29(5):890-903. PubMed ID: 36816622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Opioid Medication Use after Conventional Chemoembolization versus Drug-Eluting Embolic Chemoembolization.
    Khalaf MH; Shah RP; Green V; Vezeridis AM; Liang T; Kothary N
    J Vasc Interv Radiol; 2020 Aug; 31(8):1292-1299. PubMed ID: 32654960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer Stage 0 or A).
    Lee H; Yoon CJ; Seong NJ; Jeong SH; Kim JW
    Korean J Radiol; 2018; 19(6):1130-1139. PubMed ID: 30386144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
    Li H; Wu F; Duan M; Zhang G
    Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
    Wu J; Song L; Zhao DY; Guo B; Liu J
    World J Gastroenterol; 2014 Aug; 20(31):10960-8. PubMed ID: 25152600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel multimodal analgesia regimen improves post-TACE pain in patients with hepatocellular carcinoma.
    Guo JG; Zhao LP; Rao YF; Gao YP; Guo XJ; Zhou TY; Feng ZY; Sun JH; Lu XY
    Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):510-516. PubMed ID: 30135046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram for predicting severe abdominal pain after initial conventional transarterial chemoembolisation for hepatocellular carcinoma: a retrospective study.
    Qin H; Xiao X; Ya H; Li J; Liang F; Jin H; Liao L; Li Y; Qin J; Yu J; Gu J; Zhou C; Jin M; Miao Y; Li S
    Sci Rep; 2023 Dec; 13(1):22397. PubMed ID: 38104191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. General versus local anesthesia for percutaneous radiofrequency ablation of hepatocellular carcinoma at unusual regions.
    Bai YH; Chen G; Xu Y; Cui L; Li XH; Wang XQ; Wang MQ; Duan F
    J Cancer Res Ther; 2020; 16(7):1686-1690. PubMed ID: 33565517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.